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Introduction
Recombinant adeno-associated virus type 2 vectors (rAAV) have been extremely successful vectors for in vivo gene transfer. These vectors have produced long-term, high-level gene expression of therapeutic proteins in immunocompetent animal models. For example, sustained production of erythropoietin from skeletal muscle after rAAV transduction has been achieved in mice. 1 Therapeutic levels of factor IX have been produced after rAAV gene transfer to the liver and skeletal muscle. [2] [3] [4] [5] Levels of therapeutic protein production have reached up to 800 g/ml in mice treated intramuscularly with AAV vectors expressing alpha-1 antitrypsin. 6 Recombinant AAV vectors have been used effectively in the central nervous system. [7] [8] [9] In addition, rAAV has been used in human clinical trials to transfer the CFTR gene. 10 eve, however. The process requires the efficient cellular delivery of the proviral construct to be packaged as rAAV, the AAV-2 rep and cap genes, as well as specific helper virus functions. 11 The proviral construct to be packaged contains the cDNA expression cassette flanked by AAV-2 inverted terminal repeats (ITRs). The ITRs are the cis acting viral DNA sequences required to direct replication and packaging of the rAAV vector.
12,13 AAV-2 rep and cap genes encode the four Rep proteins (Rep 78, 68, 52 and 40) involved in viral DNA replication, resolution of replicative intermediates and generation of singlestrand genomes and the three structural genes (VP1, VP2 and VP3) that make up the viral capsid. [14] [15] [16] Usually, the proviral rAAV and the rep and cap genes are introduced into cells by plasmid transfection. Replication and packaging of rAAV then occurs after expression of specific genes from a helper virus such as adenovirus (Ad). 14, [17] [18] [19] [20] Traditionally, Ad infection is used to provide helper virus functions. 11 In the case of Ad, the specific helper functions have been identified as the E1a, E1b, E2a, E4orf6 and Va RNA genes. These Ad genes encode proteins or RNA transcripts which are transcriptional regulators and are involved in DNA replication or modify the cellular environment in order to permit efficient viral production.
Recent improvements in rAAV packaging technology have made production of high-titer rAAV more feasible. One significant advancement has been the development of an Ad-free method for rAAV production. 20, 21 This method is based on transfection of a plasmid encoding the Ad helper functions required for the production of rAAV. Other improvements have included the generation of rep inducible cell lines, translational control of Rep production and increasing Cap expression by driving cap transcription with a strong heterologous promoter. [22] [23] [24] These improved methods still possess limitations, however. The rep inducible cell lines do not produce rAAV more efficiently than traditional methods. Translational and transcriptional control of Rep and Cap production do not increase the efficiency of rAAV production more than 10-fold. 23, 24 The Ad free method requires successful transfection on a large scale that is not easily achieved.
While Ad is an efficient helper virus for rAAV production, little consideration has been given to other helper viruses for AAV-2 replication and packaging. Herpes simplex virus type 1 (HSV-1) is also a fully competent helper virus of AAV-2. [25] [26] [27] [28] The minimal set of HSV-1 genes required for AAV-2 replication and packaging has been identified as the early genes UL5, UL8, UL52 and UL29. 28 These genes encode components of the HSV-1 core replication machinery -the helicase, primase and primase accessory proteins and the single-stranded DNA binding protein (reviewed in Refs 29 and 30) .
We have investigated the use of a recombinant HSV-1 (rHSV-1) vector to facilitate production of rAAV. A rHSV-1 has been engineered to express the AAV-2 rep and cap genes (d27.1-rc). This rHSV-1 vector, d27.1-rc, does not produce ICP27, a protein required for HSV-1 replication. Although d27.1-rc is replication defective, it does express the HSV-1 early genes required for rAAV replication and packaging. 28, 31 The vector d27.1-rc has been found to be as efficient at producing rAAV as Ad-free methods and obviates the need for large-scale transfection protocols. In addition, the rHSV-1 vector is 100 times more efficient at producing rAAV than previously described amplicon system based on the HSV-1 helper functions. 32 The rHSV vector, d27.1-rc, is a novel, flexible and simple way to introduce the AAV-2 rep and cap genes and helper virus functions required to produce high-titer rAAV preparations. The potential for scaleable rAAV growth using d27.1-rc should facilitate production of sufficient quantities of rAAV vectors required for clinical applications.
Results
Construction and characterization of d27.1-rc The rHSV-1, d27.1-rc was constructed by homologous recombination of the AAV-2 rep and cap genes into the tk locus of the rHSV-1 virus d27.1 (Figure 1 ). In this recombinant virus, the AAV-2 rep and cap genes are under control of their native promoters -the p5, p19 and p40 promoters. The p5, p19 and p40 promoters drive expression of the AAV-2 proteins Rep 78 and 68, Rep 52 and 40 and the capsid structural proteins VP1, VP2 and VP3, respectively. [33] [34] [35] [36] [37] Homologous recombination into the tk gene was confirmed by Southern blot analysis of restriction digests of d27.1-rc infected cell DNA (data not shown). In addition, d27.1-rc plaque formation on V27 cells, a complementing cell line, was not affected by 5-bromo-deoxycytidine. This indicates that the tk gene, appropriately, did not produce functional thymidine kinase (data not shown).
Production of AAV-2 Rep by d27.1-rc
In order for d27.1-rc to compliment rAAV replication, the AAV-2 Rep proteins must be efficiently expressed and localized to the nucleus of the cell after d27.1-rc infection. The Rep produced by d27.1-rc localizes to the nucleus The cellular distribution of the AAV-2 Rep proteins was determined in an immunofluorescence assay (IFA) which utilized a monoclonal antibody that recognizes the four Rep proteins. The Rep proteins, expressed after infection of 293 cells by d27.1-rc, localized to discrete nuclear punctate bodies (Figure 3a) . The distribution of Rep proteins to the nucleus of 293 cells infected with d27.1-rc is a prerequisite for rAAV replication.
Replication center formation by d27.1-rc
The observation has been made that the rep gene products are capable of inhibiting viral and cellular DNA replication. [38] [39] [40] In particular, rep gene products have been shown to be potent inhibitors of Ad DNA replication and prevent the maturation of Ad DNA replication centers. 41 This inhibitory effect of Rep proteins is presumably responsible for the inability to generate a recombinant Ad that expresses the AAV-2 rep gene. If rep gene products similarly inhibited HSV-1 viral DNA replication, the recombinant virus, d27.1-rc, would not be able to propagate. Replication of d27.1-rc was not affected by the presence of the rep gene, however. The kinetics of plaque formation on V27 cells, the complementing cell line, and the amount of virus produced per cell was identical to the parent virus, d27.1 (data not shown).
In addition, the development of HSV-1 DNA replication centers after d27.1-rc infection of V27 cells was not affected by the presence of the rep gene. HSV-1 replication centers develop in the nuclei of infected cells in a time-dependent manner. 42 Viral and cellular proteins required for viral DNA replication (such as the HSV-1 core replication proteins which include ICP8, the singlestranded DNA binding protein) and replicating viral DNA localize to these centers. [42] [43] [44] [45] Mature HSV-1 replication centers were observed in the nuclei of V27 cells a b
Figure 3 (a) Immunofluorescence assay detecting the distribution of the AAV-2 Rep proteins, 10 h after infection of 293 cells with d27.1-rc. The 293 cells were processed for IFA and the cells were incubated with a monoclonal antibody that detects all four Rep proteins (78, 68, 52 and 40). The cells were then incubated with a FITC-conjugated, donkey anti-mouse secondary antibody. Magnification ×630. (b) DAPI counterstain of the nucleus in (a). Magnification ×630.
12 h after d27.1-rc infection, as indicated by the distribution of ICP8 ( Figure 4a ). This distribution of ICP8 is characteristic of fully developed HSV-1 replication centers 45 and did not differ from replication centers formed in V27 cells by the parent virus, d27.1 (data not shown). In addition, minimal AAV-2 Rep expression was observed in V27 cells after d27.1-rc infection (Figure 4b ).
The vector d27.1-rc is efficient at producing infectious rAAV from different rAAV proviral templates To determine the flexibility and efficiency of rAAV production using d27.1-rc, we tested the production of rAAV from proviral plasmid transfected into cells, from a proviral cell line and by amplifying rAAV by coinfection. The vector d27.1-rc was observed to effectively rescue rAAV from pTR-UF5-transfected 293 cells. The plasmid pTR-UF5 contains a proviral rAAV genome that encodes the green fluorescent protein (GFP). 46 Transfection of 293 cells with pTR-UF5 followed by super-infection with d27.1-rc resulted in rescue of infectious AAV-GFP (Figure 5a and b) . The amount of AAV-GFP produced was a function of the MOI of d27.1-rc. An increase in the yield of AAV-GFP was observed up to an MOI of 10. At this MOI, the yield of AAV-GFP was 381 expresion units (EU) per cell. This level of production compares favorably with recently developed rAAV production protocols based upon Ad-free transfection procedures. 20, 21 Infection of pTR-UF5-transfected 293 cells with a control virus, d27.1-lacz, at an MOI of 10 did not produce AAV-GFP (data not shown).
The vector d27.1-rc was also capable of efficient AAV-GFP production from the cell line GFP-92 (Figure 6 ). In the cell line GFP-92, a proviral rAAV genome that encodes GFP is integrated into the chromosomal DNA. As in the transfection experiment, the amount of AAV-GFP produced was observed to be a function of the MOI of d27.1-rc. At the most efficient MOI for AAV-GFP replication and packaging, 480 EU/cell could be produced using the vector d27.1-rc. Infection of this cell line with the control virus d27.1-lacz at an MOI of 10 did not produce AAV-GFP (data not shown). ( Table 1) . When rAAV and rHSV are co-infected in 293 cells, amplification of rAAV genomes is observed. Infection with d27.1-rc (MOI of 10) along with rAAV (MOI = 0.1) leads to a 200-fold amplification of input AAV-GFP. The total amplification of rAAV was greater than 10 6 -fold after three cycles of passage. While not as efficient as the production of AAV-GFP from transfected plasmid or a proviral cell line, co-infection of rAAV vectors with d27.1-rc will permit serial amplification of rAAV via scaleable infection.
Amplification of rAAV via co-infection with rHSV
The efficiency of rAAV production by d27.1-rc is maintained when the scale of production is increased To determine if d27.1-rc can be utilized to produce rAAV on a larger scale, 10 9 GFP-92 cells were infected with d27.1-rc ( Table 2 ). The yield of AAV-GFP, 380 EU/cell and 338 EU/cell in duplicate experiments, indicates that d27.1-rc is still able to efficiently produce rAAV after the Recombinant adeno-associated virus can be amplified after coinfection with d27.1-rc. 293 Cells were infected with different MOIs of AAV-GFP as indicated. Twelve hours after infection, the cells were superinfected with d27.1-rc at a MOI of 10. Fortyeight hours after infection a cell lysate was made from the infected cells by three rounds of freeze-thaw. The cell lysate was heat inactivated at 55°C for 1 h and then titered in duplicate on C12 cells that were co-infected with adenovirus (MOI 20). Forty-eight hours after infection the C12 cells were analyzed for GFP expression using fluorescent microscopy and a titer was determined (EU). The data represent duplicate experiments. 
Discussion
Recombinant adeno-associated virus-mediated gene transfer has been uniquely successful in achieving longterm, high-level gene expression in vivo. Many potential applications for the use of rAAV in genetic disease will require a substantial vector dose to achieve a therapeutic effect. One significant problem associated with rAAV vectors, has been the difficulty in generating sufficient quantities of high-titer vector required for in vivo applications. This difficulty has led to improvements in numerous aspects of rAAV vector development in order to increase the efficiency of rAAV production. These strategies have all involved the use of adenovirus to provide the helper functions for rAAV production, however. Few studies have explored the possibility of using other helper viruses of AAV-2 replication and packaging for large-scale production.
In this paper, we report the development of an alternative system for production of rAAV. This system is based upon the HSV-1 helper functions of AAV-2 replication and packaging. By generating a recombinant HSV-1 encoding the AAV-2 rep and cap genes we have made a single infectious helper. The expression of Rep from this vector appears to be regulated and is appropriately distributed to the nucleus. The rHSV-1, d27.1-rc, propagates readily and its replication is not affected by the presence of rep.
Development of mature HSV-1 replication centers in the presence of rep appears to be unique to this vector. One possible explanation why the presence of the rep gene did not affect the kinetics of d27. 1 (Figure 2 ). By IFA, Rep expression was observed in the nucleus of infected 293 cells (Figure 3a) and Vero cells (data not shown) after infection with d27.1-rc, but not in V27 cells (Figure 4b) . The minimal Rep expression after d27.1-rc infection of V27 cells may explain how generation of d27.1-rc was feasible and why similar efforts to construct recombinant Ad vectors with the rep gene have failed.
The d27.1 vector was chosen as the mutant background to provide the viral helper functions for several reasons. The vector d27.1 has a mutation in the immediate-early gene IE63 and does not produce ICP27. 31 The protein ICP27 has been implicated in the inhibition of host cell mRNA splicing. 47, 48 The use of d27.1 should minimize inhibition of splicing of the rep and cap messages compared with a vector which produces ICP27. In addition, d27.1 overexpresses ICP8, 31 one of the HSV-1 genes essential for AAV-2 replication. 28 High-level expression of ICP8, the single-stranded DNA binding protein, should be beneficial for rAAV production.
The most efficient manner in which d27.1-rc can be used for large-scale rAAV production involves infection of a proviral cell line that provides the rAAV template to be packaged. In this two-component system, the proviral cell line could be grown at high densities in large quantities in spinner cultures or cartridge systems. The AAV-2 rep and cap genes and the helper functions required for rAAV production are then provided by d27.1-rc infection. Using d27.1-rc to infect the proviral cells would eliminate the need for transfection at any step in the production process. The choice of cell line used for this system is important, however. The results of Western analysis (Figure 2 ) indicate that d27.1-rc will efficiently express the AAV-2 Rep proteins only in certain cell lines.
The dose-response curve for the production of AAV-GFP by d27.1-rc demonstrates that increasing the MOI of d27.1-rc augments rAAV production to a point. The vector d27.1-rc still expresses the immediate-early genes that encode the viral proteins ICP0 and ICP4. 31 Expression of these immediate-early genes is detrimental to the cell and induces cell death. 49, 50 At high MOIs, increased expression of these immediate-early genes probably leads to rapid cell death, limiting the production of rAAV. At a MOI of 25, while there is increased expression of the AAV-2 rep genes and the HSV-1 helper genes necessary for rAAV production, increased cytotoxicity due to additional gene expression from the vector also occurs. At a MOI of 10, the most effective balance exists between expression of the AAV-2 rep and cap genes and HSV-1 helper functions required for rAAV production and the cytotoxicity inherent to the vector.
Replication of HSV-1 is not required for efficient repli-991 cation and packaging of AAV-2. 51 Cells lines such as 293 cells, which do not complement d27.1-rc replication, can therefore be used to produce rAAV. Using a non-complementing cell line to produce rAAV will permit the production of rAAV without generating additional d27.1-rc. The helper virus, d27.1-rc, will therefore be effectively eliminated from the rAAV produced.
The application of a recombinant virus to introduce the AAV-2 rep and cap and helper virus functions into cells to produce rAAV has many advantages over an amplicon system which we previously described. 32 Unlike a recombinant HSV-1 vector, an amplicon system has a variable helper virus to amplicon virus ratio from passage to passage. This variability makes optimization of an amplicon system for rAAV production difficult since the ratio of helper virus to amplicon virus will affect the amount of rAAV produced. In addition, there is no selective pressure to maintain the recombinant AAV-2 genome in the amplicon. With passage, deletion and recombination of the amplicon genome is likely to occur, resulting in decreased efficiency of rAAV production after serial passage of the amplicon. These problems are not encountered using the recombinant virus d27.1-rc.
Large-scale production of rAAV vectors will be required for in vivo preclinical and clinical trials of potentially therapeutic rAAV vectors. The vector d27.1-rc should facilitate the production of rAAV. The vector d27.1-rc is flexible and can be utilized to produce rAAV from transfected cells, cell lines or even infected rAAV. The rescue of rAAV from proviral cell lines at or above the efficiency of Ad-free methods will permit large-scale production of rAAV without requiring a transfection procedure. Combined with recently developed purification procedures (see accompanying article in this issue, pp 973-985), d27.1-rc will be an attractive way to produce the large quantity of rAAV that will be needed for clinical success of rAAV-based gene therapy.
Materials and methods

Plasmids
The plasmid pTR-UF5 is an AAV-GFP proviral construct with AAV-2 ITRs flanking both an eGFP and a neomycin resistance gene (neo) expression cassette. Expression of GFP is driven by the human CMV promoter. The neo gene is expressed from the HSV-1 tk promoter. The plasmid pSub201 contains the AAV-2 rep and cap genes and has previously been described. 16 The plasmid pHSV-106 is a pBR-derived plasmid into which the BamHI fragment of HSV-1 (17+ stain) containing the thymidine kinase (tk) gene was cloned. The plasmid pHSV-106-lacZ was constructed by cloning a lacZ expression cassette into the KpnI restriction site of pHSV-106 interrupting the tk gene. The plasmid pHSV-106-rc has the AAV-2 rep and cap genes from pSub201 cloned into the KpnI site of pHSV-106.
Cell lines
The 293 and Vero cell lines were obtained from American Type Culture Collection (Rockville, MD, USA). The V27 cell line is a Vero-derived cell line that expresses the HSV-1 ICP27 protein and has previously been described. 31 The C12 cell line is a Hela-derived cell line with inducible AAV-2 rep gene expression and has been previously described. 22 The GFP-92 cell line was created by infecting 293 cells with AAV-GFP and has been previously described. 32 In AAV-GFP, expression of GFP is driven by the human CMV promoter and the neo gene is expressed from the HSV-1 tk promoter. All cell lines were maintained in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum (FBS).
HSV-1 viruses
The virus d27.1 is an ICP27 deletion mutant (Kos strain) which has been previously described and is propagated on the complementing cell line, V27. 31 The virus d27.1-rc was constructed by first creating the lacZ expressing virus d27.1-lacZ. The lacZ expressing vector was created by traditional techniques involving cotransfection of d27.1 infected cell DNA and the integrating plasmid, pHSV-106-lacZ (linearized by BamHI restriction digest) into V27 cells. Recombinant viruses were isolated by screening for blue plaques after agar overlay containing 400 g/ml halogenated indolyl-␤-d-galactoside (Bluogal; Gibco-BRL, Bethesda, MD, USA). Recombinant viruses were purified by three rounds of limiting dilution. Integration was confirmed by Southern analysis of restriction enzyme digested d27.1-lacZ infected cell DNA (data not shown). The virus d27.1-rc was created by cotransfection of d27.1-lacZ infected cell DNA and the SphI linearized integration plasmid pHSV-106-rc into V27 cells. Recombinant viruses were isolated by screening for white plaques after agar overlay containing 400 g/ml Bluo-gal. Recombinant viruses were purified by three rounds of limiting dilution. Integration was confirmed by Southern analysis of restriction enzyme digested d27.1-rc infected cell DNA (data not shown). The stability of integration with passage was assessed by isolating 10 clones of d27.1-rc after 10 serial passages of d27.1-rc at a MOI of 0.1. All clones were able to rescue rAAV (data not shown). Wildtype HSV-1 virus capable of replicating on Vero cells was not detected in any preparation (limit of detection is Ͻ20 plaque forming units (p.f.u.)/ml).
Recombinant AAV production methods
Production of AAV-GFP from pTR-UF5 transfected 293 cells: Tissue culture dishes (10 cm) plated with 2 × 10 6 293 cells were transfected with 5 g pTR-UF5 and 25 l Lipofectamine (Gibco-BRL) as per the manufacturer's instruction. Four hours after transfection, the cells were washed and DMEM (10% FBS) was added. Twenty hours later, the cells were superinfected with d27.1-rc at different MOIs or d27.1-lacz at a MOI of 10. (The cells on an extra transfected dish were trypsinized, resuspended and counted using a hemocytometer.) Approximately 3.5 × 10 7 cells were infected per MOI. Forty-eight hours later, the cells were harvested and pelleted by centrifugation (375 g, 5 min). The cells were then resuspended in 10 ml of DMEM and cell-associated rAAV was released by three rounds of freezing and thawing. Cell debris was pelleted by centrifugation (250 g, 5 min). The cell lysates were then titrated for EU of AAV-GFP as described below and purified by CsCl gradient as previously described. 1 This experiment was repeated in triplicate.
Production of AAV-GFP from the cell line GFP-92: The GFP-92 cells were plated in 75 cm 2 tissue culture flasks. Twelve hours later, the cells were infected with d27.1-rc at different MOIs or d27.1-lacz at a MOI of 10. The number of cells in one extra flask was determined as described above. Approximately 1.5 × 10 7 GFP-92 cells were infected per MOI. Cells were harvested 48 h after infection and cell-associated AAV-GFP was processed and titered as described above. This experiment was repeated in triplicate.
Production of AAV-GFP by amplifying AAV-GFP via infection 293 Cells (1.5 × 10 6 cells) were plated in six-well tissue culture dishes. Twelve hours later, the cells were infected with AAV-GFP at different MOIs. Twelve hours later, the cells were infected with d27.1-rc at a MOI of 10. Cells were harvested 48 h after infection and cell-associated AAV-GFP was processed as described above. This experiment was repeated in triplicate. The amount of output rAAV was determined using the fluorescent cell assay described below.
Large-scale AAV-GFP production GFP-92 cells were plated on 175 cm 2 tissue culture flasks 12 h before infection. 1 × 10 9 GFP-92 cells were infected 12 h later with d27.1-rc at a MOI of 10. Cells were harvested 48 h after infection and cell-associated AAV-GFP was processed as described above. This experiment was repeated in duplicate. Stocks were analyzed for replication-competent AAV (rcAAV) as previously described.
3 Replication-competent AAV was not detected (limit of detection was one replication unit per 10 7 GFP EU).
Titering of AAV-GFP in the cell lysates by the fluorescent cell assay Cell lysates were heat inactivated (55°C, 1 h). Serial dilutions of AAV-GFP were then titered on C12 cells with Ad co-infection (MOI 20) as previously described. 52 The cells were then analyzed for GFP expression using fluorescence microscopy at 48 h after infection.
Western analysis of AAV-2 Rep proteins
The indicated cells (approximately 4 × 10 6 cells) were plated on to 6 cm tissue culture plates 12 h before infection with d27.1-rc (MOI as indicated). Control samples were not infected. Cells were harvested 48 h after infection and cell lysates were made and loaded on to a 10% sodium dodecyl sulfate (SDS)-polyacrylamide gel followed by immunoblotting using a monoclonal antibody (clone 1F11.8, 1:5000 dilution) that recognizes all four AAV-2 Rep proteins. The antibody was detected by chemiluminescence (Amersham, Arlington Heights, IL, USA).
Immunofluorescence assay Cells (293, Vero or V27 cells) were plated on to two-well tissue culture slides at a density of 1.5 × 10 5 cells per well. For the anti-AAV Rep immunofluorescence assay, 293 cells were infected 12 h later with d27.1-rc at a MOI of 10. Cells were washed with DMEM after a 45 min adsorption period and DMEM with 10% FBS was then added. After 10 h, cells were washed twice with PBS and fixed for 10 min in 4% paraformaldehyde in PBS. Cells were washed twice with PBS and permeabilized with 0.2% Triton X-100 in PBS for 2 min. Cells were then washed twice with PBS and incubated for 1 h at 37°C in a humidified chamber with monoclonal anti-Rep antibody (American Research Products, Belmont, MA, USA, clone 226.7, 1:1 dilution). This antibody recognizes all four Rep proteins. The cells were then washed three times with PBS and incubated for 30 min at 37°C with FITC-conjugated, donkey anti-mouse secondary antibody (diluted 1:100 in 2% goat serum, 2% donkey serum in PBS). The slides were then washed three times, covered with a 4′, 6-diamidino-2-phenylindole (DAPI) containing mounting solution (Vector Laboratories, Burlingame, CA, USA), sealed and analyzed for immunofluorescence. Microscopy was performed on a Leitz microscope with Image Pro acquisition equipment and image analysis software.
To analyze the maturation of HSV-1 viral replication centers and Rep expression in V27 cells after d27.1-rc infection, a rabbit polyclonal anti-ICP8 (the HSV-1 singlestanded DNA binding protein) antibody (PAb 3-83) and the monoclonal anti-Rep antibody (American Research Products, clone 226.7, 1:1 dilution) were utilized in a double label experiment. All procedures were as previously described except that V27 cells were infected at a MOI of 1. After fixing and permeablization, V27 cells were incubated as above with the anti-Rep monoclonal antibody. The cells were then washed twice with PBS and incubated with the anti-ICP8 antibody (diluted 1:50 in 2% goat serum, 2% donkey serum in PBS) for 1 h in a humidified chamber at 37°C. The cells were then washed three times with PBS and incubated with a rhodamineconjugated, donkey anti-rabbit secondary antibody and FITC-conjugated, donkey anti-mouse secondary antibody (both diluted 1:100 in 2% goat serum, 2% donkey serum in PBS) for 30 min at 37°C. The slides were then washed three times, covered with DAPI containing mounting solution, sealed and analyzed for immunofluorescence. (Vero cells were infected and processed alongside V27 cells to serve as positive controls for Rep staining.)
